The researchers examined the lifestyle habits, GLP-1 RA usage, and cardiovascular health outcomes of more than 98,000 adults living with T2D and without any prior cardiovascular disease, using data from the Veterans Affairs Million Veteran Program from 2011 to 2023
Demand forecast and sales forecast for GLP-1 Diabetes Treatment Drugs Market in the USA GLP-1 diabetes treatment drugs market in the United States is projected to grow at a CAGR of 24.0% through 2035, supported by the country's advanced diabetes care sector, pharmaceutical innovation capabilities, and established leadership in healthcare solutions
Adding to the pressure on J&J is a September 2024 announcement from Cignas Evernorth Health Services that it will offer an interchangeable biosimilar alternative to Stelara at $0 out-of-pocket
You may notice less appetite suppression or slower weight loss for that injection cycle
These are usually adaptation symptoms rather than long-term side effects and often subside as your body grows accustomed to the GLP-1 hormone